SCHIMMEL PAUL 4

What Happened
Paul Schimmel, a director of aTYR PHARMA, acquired 100,000 shares in an open-market or private purchase on May 27, 2026. The total reported value of the purchase was $49,630. The filing reports a weighted-average price of approximately $0.4963 per share and notes individual purchase prices ranged from $0.4907 to $0.50.

Key Details

• Transaction date and filing: Purchased on 2026-05-27; Form 4 filed 2026-05-28 (timely filing).
• Transaction type: P = Purchase (open-market or private purchase as reported).
• Shares purchased: 100,000; total reported value: $49,630; weighted-average price ~ $0.4963/share; price range $0.4907–$0.50 (see footnote F1 for breakdown).
• Post-transaction holdings: Total shares owned following the transaction are not specified in the provided excerpt of the filing.
• Notable footnotes:
  • F1: Weighted-average price shown; breakdown of shares at each price is available upon request to the SEC/issuer/holders.
  • F2: Some shares are owned by the Schimmel Revocable Trust U/A dated 9/6/2000, for which Paul Schimmel and his spouse are trustees.
  • F3: Some shares are owned by "Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel"; the reporting person is the sole owner of that entity.

Context
Purchases by insiders are often watched closely by investors because they can signal confidence, but the filing itself does not state any motive. This transaction is a straightforward purchase (not an option exercise, gift, or tax withholding). The filing was made the day after the trade, which is within typical reporting expectations.